Tech Times on MSN
KRAS drug resistance has upstream cause: METTL13 enzyme fuels tumor protein overload
KRAS cancer treatment may have a new upstream target: the METTL13 enzyme that helps tumors overproduce KRAS protein and ...
A methylation mark on translation factor eEF1A selectively speeds decoding of rare, wobble-weak codons, boosting KRAS ...
A metagenomic study of acidic, CO2-rich groundwater reconstructed three thaumarchaeotal Group 1.1c genomes that lacked ...
A microscopic organism from a freshwater pond is playing by a different set of genetic rules. The newly identified protist, Oligohymenophorea sp. PL0344, which scientists stumbled across while ...
Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal ...
March 25, 2020. A letter was issued by the Center for Food Safety and Applied Nutrition of the U.S. Food and Drug ...
Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of ...
This article explains the development and evaluation of GISMO and GISMO-mis, new constraint metrics that utilize mammalian ...
Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and enabled considerable therapeutic advances for ...
According to BCC Research, the global gene synthesis market is projected to grow from $3.4 billion in 2026 to $7.2 billion by ...
Cartesia Research demonstrates that Hierarchical Networks (H-Nets) learning dynamic tokenization from raw bytes achieve up to ...
Only about 5% of rare diseases have an approved therapy, and this is unlikely to change without novel development processes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results